Iceni Pharmaceuticals Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Iceni Pharmaceuticals General Information

Description

Developer of a cancer drug intended to re-position and reformulate existing drugs for new disease indications. The company's therapies specialize in the development of a pentapeptide drug with a safety profile and a novel mechanism of action compared to existing myeloma treatments, enabling medical communities to reduce the risk, cost, and development time for treatments and maximize the chance of clinical success.

Contact Information

Formerly Known As
BigDNA
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Wallace Building, Roslin Biocentre
  • Midlothian
  • Roslin EH25 9PP
  • Scotland, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Wallace Building, Roslin Biocentre
  • Midlothian
  • Roslin EH25 9PP
  • Scotland, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Iceni Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Out of Business 05-Sep-2023 Completed Out of Business
8. Secondary Transaction - Private 01-Apr-2021 Completed Generating Revenue
7. Later Stage VC 01-Mar-2016 Completed Generating Revenue
6. Grant 01-May-2014 Completed Clinical Trials - Phase 1
5. Grant 10-Dec-2012 Completed Clinical Trials - Phase 1
4. Early Stage VC 09-Feb-2010 Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Nov-2008 Completed Clinical Trials - Phase 1
2. Grant 01-Jan-2008 $141K $614K Completed Clinical Trials - Phase 1
1. Early Stage VC 01-Jan-2007 $614K $614K Completed Startup
To view Iceni Pharmaceuticals’s complete valuation and funding history, request access »

Iceni Pharmaceuticals Patents

Iceni Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3448408-A1 Combination therapy Inactive 26-Apr-2016
GB-2554333-A Combination therapy Inactive 26-Apr-2016
US-20190134148-A1 Combination therapy Inactive 26-Apr-2016
WO-2017187156-A1 Combination therapy Inactive 26-Apr-2016
GB-201506673-D0 Combination therapy Inactive 20-Apr-2015
To view Iceni Pharmaceuticals’s complete patent history, request access »

Iceni Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Iceni Pharmaceuticals FAQs

  • When was Iceni Pharmaceuticals founded?

    Iceni Pharmaceuticals was founded in 2006.

  • Where is Iceni Pharmaceuticals headquartered?

    Iceni Pharmaceuticals is headquartered in Roslin, United Kingdom.

  • What is the size of Iceni Pharmaceuticals?

    Iceni Pharmaceuticals has 3 total employees.

  • What industry is Iceni Pharmaceuticals in?

    Iceni Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Iceni Pharmaceuticals a private or public company?

    Iceni Pharmaceuticals is a Private company.

  • What is Iceni Pharmaceuticals’s current revenue?

    The current revenue for Iceni Pharmaceuticals is .

  • How much funding has Iceni Pharmaceuticals raised over time?

    Iceni Pharmaceuticals has raised $7.05M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process